BPC-157
Also known as Body Protection Compound-157, Bepecin
A synthetic gastric pentadecapeptide widely studied in animals for tissue healing, with very limited human data.
Medically reviewed by Dr. Jonathan Snipes, MD
Reviewed for clinical accuracy · Last reviewed September 23, 2026 · Review policy
Quick answer
BPC-157 is a synthetic peptide studied extensively in animal models for tissue and tendon healing, but it is not FDA-approved and has very little human clinical evidence. It is prohibited in sport. At the July 23-24, 2026 PCAC meeting, an FDA advisory committee recommended it for the 503A compounding list; the vote is advisory and the FDA decision is pending.
- Type
- Synthetic gastric pentadecapeptide
- FDA status
- Not approved; PCAC recommended for 503A list (FDA decision pending)
- Human evidence
- Minimal (mostly animal studies)
- Evidence grade
- D (Preclinical Only)
- Banned in sport
- Yes (WADA)
Key takeaways
- →BPC-157 has a large preclinical (animal) literature on tendon, muscle, gut and wound healing, but human clinical trials are very limited.
- →It is not FDA-approved. FDA staff recommended against adding it to the 503A compounding list, but at the July 23, 2026 PCAC meeting the committee voted to recommend it for ulcerative colitis, in a vote reported as 8-6 with 1 abstention. The vote is advisory; FDA has not yet decided.
- →It is prohibited in sport under the WADA framework.
- →Long-term human safety is not well characterized, and a theoretical angiogenesis concern (promoting blood-vessel growth) has been raised in the context of existing tumors.
- →On our scale it earns a D (Preclinical Only): high interest and promising animal data, but the human evidence is not there yet.
BPC-157 is the most talked-about recovery peptide and one of the clearest examples of a gap between hype and human evidence. It is a synthetic fragment derived from a protein found in gastric juice, studied heavily in rodents for healing across many tissue types. That animal literature is genuinely extensive, but it has not translated into the human clinical trials that would justify strong claims, which is why we grade it honestly rather than optimistically.
How BPC-157 works
The proposed mechanisms come almost entirely from animal and laboratory work. BPC-157 is reported to promote angiogenesis (new blood-vessel formation), modulate growth-factor and nitric-oxide pathways, and interact with the VEGF signaling system, which together could support tissue repair. These are plausible and consistently reported in preclinical models, but the pathways have not been confirmed in controlled human studies.
What the evidence shows, by use
Each use is graded on the same A-E scale, based on human-trial quality rather than popularity.
Tendon, ligament and muscle healing
DPreclinical OnlyMultiple rodent studies show accelerated healing, but there is no completed randomized human trial establishing the same effect in people.
Gut protection / GI healing
DPreclinical OnlyAnimal models show cytoprotective and gut-healing effects; human data is anecdotal rather than trial-based.
General injury recovery
EAnecdotalWidely used for this purpose based on user reports, but controlled human evidence is essentially absent.
Dosing
There is no FDA-approved BPC-157 product and therefore no established, evidence-based human dose. Protocols circulating online are extrapolated from animal studies and community practice, not human dose-finding trials. Because purity, sterility, and actual content of gray-market vials are unverified, any use should happen only through a licensed clinician and a legitimate compounding pharmacy, not research-chemical suppliers.
Side effects
- •Injection-site reactions · Reported
- •Fatigue or lethargy · Reported
- •Nausea or GI upset · Reported
- •Headache, dizziness · Reported
Legal & regulatory status
BPC-157 is not FDA-approved and is not on the 503A Bulks List. FDA staff recommended against listing it, but the PCAC voted on July 23, 2026 to recommend it (reported as 8-6-1). The vote is not binding; any listing needs FDA rulemaking.
Is BPC-157legal? Full regulatory status →Where to get it: TeleRanked independently ranks the telehealth providers that offer clinician-prescribed peptides. See our Peptide Therapy rankings. We rank providers, we do not sell compounds, and rankings are never for sale.
Frequently asked questions
Does BPC-157 actually work?+
Animal studies consistently show healing benefits, but there is no completed randomized human trial demonstrating the same effects in people. The honest answer is that human evidence is very limited.
Is BPC-157 FDA-approved?+
No. BPC-157 is not FDA-approved. In July 2026 an FDA advisory committee recommended it for the 503A compounding list, but the vote is advisory and the FDA decision is pending.
Is BPC-157 legal?+
It is not an approved drug and is not on the FDA's 503A Bulks List today. An FDA advisory committee recommended it for that list in July 2026, but the vote is not binding and FDA has not acted. Research-use-only products are not a lawful route to human use, and it is banned in sport.
Is BPC-157 safe?+
Its human safety is not well characterized because it has not been through formal human trials. Reported side effects are mostly mild and anecdotal, and a theoretical angiogenesis concern warrants caution in people with a cancer history.
How we grade evidence
Grade D: Preclinical Only. Evidence is largely limited to animal or laboratory studies; human data is minimal or absent. Our A-E scale reflects the strength of human evidence, not how popular a compound is.
Sources
- 1.July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee · U.S. Food & Drug Administration
- 2.FDA briefing document: BPC-157, Pharmacy Compounding Advisory Committee (July 2026) · U.S. Food & Drug Administration
- 3.Compounding and the FDA: Questions and Answers · U.S. Food & Drug Administration
- 4.WADA Prohibited List · World Anti-Doping Agency